Ann Liver Transplant.  2024 May;4(1):23-29. 10.52604/alt.24.0001.

Clinical impact and risk factors for cytomegalovirus infection in deceased donor liver transplantation without prophylaxis: Single center experience

• Kim DG
• Min EK
• Lee JG
• Joo DJ
• Kim MS

• KMID: 2560938
• DOI: http://doi.org/10.52604/alt.24.0001

Abstract

Background
The study aims to elucidate the relationship between cytomegalovirus (CMV) infection and graft survival, as well as to identify risk factors for CMV infection in deceased donor liver transplantation (DDLT) recipients without prophylaxis.
Methods
A retrospective study was conducted on 465 DDLT recipients at Severance Hospital, South Korea, employing a nested case-control design to explore CMV infection risk factors.
Results
All study population showed CMV antibody seropositivity and did not received CMV prophylaxis. CMV infection was observed in 38.6% of DDLT recipients within the first year. Patients with CMV infection showed reduced graft survival rates within 5 years after matched time points compared to those without infection (57.9% vs. 67.5%, p=0.039), which confirmed in multivariable analysis (hazard ratio 1.44, p=0.047). Risk factor analysis revealed that Child-Pugh class C, donor liver macrovesicular steatosis ≥20%, and elevated pretransplant neutrophil levels were independently associated with an increased risk of CMV infection.
Conclusion
This study confirms that CMV infection post-DDLT is a significant predictor of reduced graft survival. Addressing risk factors of CMV infection through targeted interventions could potentially improve patient management and post-transplant outcomes after DDLT.

Keyword

Liver transplantation; Cytomegalovirus; Deceased donor

Figure

• 

  Figure 1 Study flow for nested case-control study. DDLT, deceased donor liver transplantation; CMV, cytomegalovirus.

• 

  Figure 2 Kaplan-Meier curves for death or retransplantation after index date. Index date was set at the date of cytomegaloviru (CMV) viremia identification in the CMV viremia group and the corresponding date in the control group. POD, postoperative day.

Reference

1. Kotton CN. 2013; CMV: prevention, diagnosis and therapy. Am J Transplant. 13 Suppl 3:24–40. quiz 40DOI: 10.1111/ajt.12006. PMID: 23347212.

2. Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N, et al. 2012; Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 12:2457–2464. DOI: 10.1111/j.1600-6143.2012.04087.x. PMID: 22594993. PMCID: PMC3510308.

3. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, et al. 1997; Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 350:1729–1733. Erratum in: Lancet 1998;351:454. DOI: 10.1016/S0140-6736(97)05535-9. PMID: 9413463.

4. Kim JM, Kim SJ, Joh JW, Kwon CH, Song S, Shin M, et al. 2011; Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation? Liver Transpl. 17:446–455. DOI: 10.1002/lt.22249. PMID: 21445928.

5. Yim SH, Choi MC, Kim DG, Min EK, Lee JG, Joo DJ, et al. 2023; Risk factors for cytomegalovirus infection and its impact on survival after living donor liver transplantation in South Korea: a nested case-control study. Pathogens. 12:521. DOI: 10.3390/pathogens12040521. PMID: 37111407. PMCID: PMC10143532.

6. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018; 102:900–931. DOI: 10.1097/TP.0000000000002191. PMID: 29596116.

7. Samstein B, Smith AR, Freise CE, Zimmerman MA, Baker T, Olthoff KM, et al. 2016; Complications and their resolution in recipients of deceased and living donor liver transplants: findings from the A2ALL cohort study. Am J Transplant. 16:594–602. DOI: 10.1111/ajt.13479. PMID: 26461803. PMCID: PMC4733444.

8. Kim JM, Kim DG, Kim J, Lee K, Lee KW, Ryu JH, et al. 2021; Outcomes after liver transplantation in Korea: incidence and risk factors from Korean transplantation registry. Clin Mol Hepatol. 27:451–462. DOI: 10.3350/cmh.2020.0292. PMID: 33525077. PMCID: PMC8273644.

9. Boaretti M, Sorrentino A, Zantedeschi C, Forni A, Boschiero L, Fontana R. 2013; Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients. J Clin Virol. 56:124–128. DOI: 10.1016/j.jcv.2012.10.015. PMID: 23182772.

10. Breitkopf R, Treml B, Bukumiric Z, Innerhofer N, Fodor M, Radovanovic Spurnic A, et al. 2023; Cytomegalovirus disease as a risk factor for invasive fungal infections in liver transplant recipients under targeted antiviral and antimycotic prophylaxis. J Clin Med. 12:5198. DOI: 10.3390/jcm12165198. PMID: 37629240. PMCID: PMC10455861.

11. Lizaola-Mayo BC, Rodriguez EA. 2020; Cytomegalovirus infection after liver transplantation. World J Transplant. 10:183–190. DOI: 10.5500/wjt.v10.i7.183. PMID: 32844094. PMCID: PMC7416364.

12. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. 2013; Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev. 2013:CD005133. DOI: 10.1002/14651858.CD005133.pub3. PMID: 23450558. PMCID: PMC6823220.

13. Florescu DF, Qiu F, Schmidt CM, Kalil AC. 2014; A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant. Clin Infect Dis. 58:785–803. DOI: 10.1093/cid/cit945. PMID: 24385444.

14. Mumtaz K, Faisal N, Husain S, Morillo A, Renner EL, Shah PS. 2015; Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis. Am J Transplant. 15:472–481. DOI: 10.1111/ajt.13044. PMID: 25522141.

15. Tookey PA, Ades AE, Peckham CS. 1992; Cytomegalovirus prevalence in pregnant women: the influence of parity. Arch Dis Child. 67(7 Spec No):779–783. DOI: 10.1136/adc.67.7_Spec_No.779. PMID: 1325757. PMCID: PMC1590405.

16. Pembrey L, Raynor P, Griffiths P, Chaytor S, Wright J, Hall AJ. 2013; Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One. 8:e81881. DOI: 10.1371/journal.pone.0081881. PMID: 24312372. PMCID: PMC3842274.

17. Peng Y, Qi X, Guo X. 2016; Child-Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. Medicine (Baltimore). 95:e2877. DOI: 10.1097/MD.0000000000002877. PMID: 26937922. PMCID: PMC4779019.

18. Katsolis JG, Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, et al. 2013; Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients. Transpl Infect Dis. 15:171–180. DOI: 10.1111/tid.12050. PMID: 23331429.

19. Kwong AJ, Kim WR, Lake J, Stock PG, Wang CJ, Wetmore JB, et al. 2023; Impact of donor liver macrovesicular steatosis on deceased donor yield and posttransplant outcome. Transplantation. 107:405–409. DOI: 10.1097/TP.0000000000004291. PMID: 36042548. PMCID: PMC9877102.

20. Duan X, Yan L, Shen Y, Zhang M, Bai X, Liang T. 2020; Outcomes of liver transplantation using moderately steatotic liver from donation after cardiac death (DCD). Ann Transl Med. 8:1188. DOI: 10.21037/atm-20-5888. PMID: 33241037. PMCID: PMC7576094.

21. Chu MJ, Dare AJ, Phillips AR, Bartlett AS. 2015; Donor hepatic steatosis and outcome after liver transplantation: a systematic review. J Gastrointest Surg. 19:1713–1724. DOI: 10.1007/s11605-015-2832-1. PMID: 25917535.